Abstract
We performed a Phase II trial to evaluate the activity and tolerability of docetaxel as a single agent in the treatment of advanced non-small cell lung cancer (NSCLC). Forty-four patients with metastatic and/or locally advanced NSCLC received i.v. docetaxel 100 mg/m2 every 3 weeks for a median of 4 (range 1–11) cycles. All patients received premedication with oral dexamethasone 8 mg twice daily for 5 days starting the day before chemotherapy. Seven partial responses were observed among 35 evaluable patients, and the overall response rate was 20% (95% CI 8-37). The median response duration was 5 months, median survival time was 10 months and the estimated 1-year survival rate was 42%. Treatment was generally well tolerated. Febrile neutropenia occurred in 10 patients (23%); neutropenic infection occurred in 4 patients, and led to 2 toxic deaths (both patients had borderline exclusion criteria). The corticosteroid premedication effectively reduced the overall incidence (34%) and severity (4% severe) of fluid retention, and delayed the median time to onset from cycle 4 to cycle 7. This study shows the promising efficacy of docetaxel as monotherapy in advanced NSCLC, and combination chemotherapy regimens incorporating docetaxel are now being evaluated in this clinical setting.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ginsberg RJ, Vokes EE, Raben A: Non-small cell lung cancer. In: de Vita Jr FT, Hellman S, Rosenberg SA (eds) Principles and Practice of Oncology. 5th edition. Lippincott-Raven, Philadelphia, 1997, pp 858-911.
Feigal EG, Christian M, Cheson B, Grever M, Friedman MA: New chemotherapeutic agents in non-small cell lung cancer. Semin Oncol 20(2): 185-201, 1993
Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899-909, 1995
Feld R, Ginsberg RJ, Payne DG, Shepherd FA: Lung. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE (eds) Clinical Oncology. Churchill Livingstone, New York/Edinbourg/London/Melbourne/Tokyo, 1995, pp 1083- 1152
Ringel I, Horwitz SB: Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288- 291, 1991
Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S, Huber M, Perez-Soler R, Hong WK, Raber M: Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 12: 1238-1244, 1994
Fossella F, Lee JS, Bérille J, Hong WK: Summary of phase II data of docetaxel (Taxotere®), an active agent in the first and second line treatment of advanced non-small cell lung cancer. Semin Oncol 22(Suppl)4: 22-29, 1995
Francis PA, Rigas JR, Kris MG, Pisters KNW, Orazem JP, Woolley KJ, Heelan RT: Phase II trial of docetaxel in patients with stage II and IV non-small cell lung cancer. J Clin Oncol 12: 1232-1237, 1994
Miller VA, Rigas JR, Francis PA, Grant SC, Pisters KMW, Venkatraman ES, Woolley K, Heelan RT, Kris MG: Phase II trial of a 75 mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75: 968-972, 1995
Fleming T: One sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143-151, 1989
Hryniuk WM: Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14: 65-74, 1987
Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10: 16-20, 1992
Edelman MJ, Gandara DR: Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 37: 385-393, 1996
Kris M, Cohen E, Gralla R: An analysis of 134 phase II trials in non-small cell lung cancer (Abstr). IV World Conference on Lung Cancer, Toronto, 1985, p 39
Rigas JR: Single-agent docetaxel in previously untreated non-small cell lung cancer. Oncology 11: 17-21, 1997
Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328: 1323- 1332, 1990
Van Oosterom AT, Dieras V, Tubiana-Hulin M, Kalla S, Coombes RC, Alakl M, Murawsky M: Taxotere® in previously treated patients with metastatic breast carcinoma: strati fication for anthracycline resistance (Abstr 231). Proc Am Soc Clin Oncol 15: 141, 1996
van Zandwijk N, Giaccone G: Treatment of metastatic non-small cell lung cancer. Curr Opin Oncol 8: 120-125, 1996
Albain KS, Crowley J, Leblanc M, Livingston R: Survival determinants in extensive stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9: 1618-1626, 1991
Bonomi P, Kim K, Chang A, Johnson D: Phase III trial comparing etoposide cisplatin versustaxol with cisplatin-granulocyte-colony stimulating factor versustaxol-cisplatin in advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group trial (Abst 1145). Proc Am Soc Clin Oncol 15: 382, 1996
Giaccone G, Splinter T, Postmus P, Diaz Fuente M, Van Zandwijk N, de Bruyne C, Sahmoud T: Paclitaxel-cisplatin versusteniposide-cisplatin in advanced non-small cell lung cancer (Abstr 1109). Proc Am Soc Clin Oncol 15: 373, 1996
Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S et al.: Randomized study of vinorelbine and cisplatin versusvindesine and cisplatin versusvinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367, 1994
Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GRE, Laufman LR, Baker LH, Fisher RI, Bearman SI, Taylor SA, Livingston RB: Randomized phase III trial of cisplatin versuscisplatin plus navelbine in treatment of advanced non-small cell lung cancer: report of a South West Oncology Group study (Abst 1110). Proc Am Soc Clin Oncol 15: 374, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Latreille, J., Gelmon, K., Hirsh, V. et al. Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Invest New Drugs 16, 265–270 (1998). https://doi.org/10.1023/A:1006126505910
Issue Date:
DOI: https://doi.org/10.1023/A:1006126505910